Updates are available Correction dated 2023-02-23
Click to view Correction: https://doi.org/10.1038/s42003-023-04600-z
-
Authors
Stellato, Mara
Dewenter, Matthias
Rudnik, Michal
Hukara, Amela
Özsoy, Çagla https://orcid.org/0000-0002-5620-4796
Renoux, Florian
Pachera, Elena
Gantenbein, Felix
Seebeck, Petra
Uhtjaerv, Siim
Osto, Elena
Razansky, Daniel
Klingel, Karin
Henes, Joerg
Distler, Oliver
Błyszczuk, Przemysław
Kania, Gabriela https://orcid.org/0000-0003-3788-4594
- License Information
-
More Information
Article History
Received: 19 May 2022
Accepted: 26 January 2023
First Online: 9 February 2023
Change Date: 23 February 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s42003-023-04600-z
Competing interests
: The disclosure statement of Prof. O. Distler (2 years backwards, 2020-2022): Prof. O. Distler has/had consultancy relationship with and/or has received research funding from or has served as a speaker for the following companies in the area of potential treatments for systemic sclerosis and its complications in the last two years: 4P-Pharma, Abbvie, Acceleron, Alcimed, Altavant, Amgen, AnaMar, Arxx, AstraZeneca, Blade, Bayer, Boehringer Ingelheim, Corbus, CSL Behring, Galderma, Galapagos, Glenmark, Gossamer, iQvia, Kymera, Lupin, Medscape, Merck, Miltenyi Biotec, Mitsubishi Tanabe; Novartis, Prometheus, Redxpharna, Roivant, and Topadur in the area of potential treatments of scleroderma and its complications. Patent issued “mir-29 for the treatment of systemic sclerosis” (US8247389, EP2331143). Research Grants: Kymera, Mitsubishi. All other authors declare no competing interests.
